September 28th, 2023

Life Sciences BC seeks to raise the profile of our members and supporters, highlight their achievements, and promote BC's dynamic life sciences ecosystem. If you have news or a story to share, let us know. You can find previous editions of BioLinks newsletters and other resources on our website at News/Publications.

We are excited to unveil the second installment of our transformative course: BioBasics 101 - The Biology of Biotech for Non-Scientists, created in collaboration with Biotech Primer. Designed with non-scientific professionals in mind, this course equips you with crucial insights into the scientific foundation of the biopharmaceutical industry, empowering you to engage in substantive discussions with colleagues, clients, regulators, and scientists, fostering more impactful collaborations. Learn more and register here. Bring your team!

We are delighted to offer a unique and exclusive opportunity to a select group of BC life sciences companies! On Nov 1, successful candidates will engage in one-on-one discussions with United Therapeutics, a pioneering biotech company at the forefront of revolutionary technologies in rare lung diseases, oncology, and organ manufacturing. You will have a chance to present your innovations and explore the potential for exciting collaborations. Find details on how to apply for United Therapeutics Meeting Day here.

I had the privilege of attending this week's BIOTECanada Gold Leaf Awards, where Abdera Therapeutics received the Gold Leaf Award for the top Promising Biotech Company! Their accolades continue to mount, as Abdera was also recently awarded this year's LSBC Emerging Company of the Year Award. Congratulations to BIOTECanada for hosting a great event and to Abdera Therapeutics for this well-deserved recognition! You can learn more about the Gold Leaf Awards and see the complete list of winners here.

Member Highlights 

STEMCELL Technologies will be the presenting partner for the upcoming full-day Girls and STEAM Summit at Science World in Vancouver on Nov 4. This meaningful event offers an inclusive and inviting environment for individuals aged 12-14 who identify as a girl, trans, genderqueer, non-binary, Two-Spirit, and gender-questioning. Participants will connect with STEAM-related professionals and discover future STEAM opportunities. Learn more.

United Therapeutics has recently achieved groundbreaking progress in the world of organ transplantation with the second transplantation of their UHeart™, sourced from a pig with a 10-gene modification, into a living recipient. In addition, United Therapeutics has achieved a second milestone with a 61-day study of the UThymoKidney™, a kidney sourced from a pig with a single-gene modification, along with the pig's thymus. As a result of these developments, United Therapeutics is moving forward with preparations for clinical trials of its Xenoheart and Xenokidney products. These advancements hold significant potential in the field of organ transplantation. See their press release here. Read CNN coverage here. 

Michael Smith Health Research BC has announced the recipients of its 2023 Research Trainee Awards. This program supports 41 early career researchers at institutions across the province as they investigate critical areas such as cancer rehabilitation, youth mental health, and palliative care. For further information and to view the comprehensive list of awardees, click here.

Paul Moore, Chief Scientific Officer at Zymeworks, was recently featured in Genetic Engineering & Biotechnology News, discussing how Zymeworks is leveraging clinical learnings to drive design features. Read it here.

New Members

We are pleased to welcome the following new LSBC Members: 

CereCura Nanotherapeutics is a preclinical neuroscience-focused biotechnology company developing lipid nanoparticle-RNA therapies for a wide range of brain disorders.

SeraGene Therapeutics is an early-stage biotechnology company developing the next-generation of gene and cell therapies to treat blood coagulation disorders, including bleeding and thrombosis.

Dr. Ashish Kumar is a postdoctoral fellow at The BC Cancer Research Centre and the Department of Pathology and Laboratory Medicine, UBC. His research focuses on investigating organelle function and metabolism and developing targeted strategies to address chemoresistance and metastasis in high-risk childhood cancers.

Welcome all to the LSBC community!

Industry Highlights

Japan is one of Canada’s most important economic and commercial partners, with Canadian exports totalling $18B in 2022. This week, Canada welcomed Japan’s Minister of Economy, Trade and Industry to a signing ceremony for two memorandums of cooperation (MoCs), demonstrating the growing relationship between Canada and Japan. The MoC on Industrial Science and Technology aims to create closer scientific collaboration between Canadian and Japanese partners in emerging technologies, such as artificial intelligence, advanced manufacturing, clean technology, and life sciences. Learn more.

Canada has launched a voluntary code of conduct for advanced generative AI systems. Effective immediately, the code identifies measures organizations are encouraged to apply to their operations when developing and managing general-purpose generative artificial intelligence systems. Created in consultation with Canadians and industry experts, Canada’s voluntary code of conduct aims to build trust in advanced generative AI systems until regulations can be developed under the Artificial Intelligence and Data Act. Learn more. 

The Canada Research Coordinating Committee (CRCC) has released its 2018-23 report, "Vision to Action". The report demonstrates that Canada's research funding agencies, in partnership with other CRCC member organizations, have worked closely over the last five years. They have done so with input from external working groups and advisory bodies to create and harmonize innovative new policies and programs that align with CRCC priorities. Read it here. 

Innovate BC, InBC, PacifiCan, and New Ventures BC have collaborated to introduce Capital Compass BC. This newly launched online platform offers an extensive and continually updated overview of British Columbia's capital and business environment, encompassing information on startups, scaleups, investors, entrepreneurial resources, and investment capital flow within the province. Learn more.

We recently released this year's edition of the Life Sciences BC Magazine, a collaborative effort with Business in Vancouver. Inside, you'll discover insightful articles featuring many of our sector leaders on topics including groundbreaking next-generation therapeutics, BC's talent pipeline, the latest in clinical trials, strategies for sector expansion, valuable messages from government representatives – and more! Read it here and let us know if your organization would like printed copies!

Kudos

Congratulations to Prince Edward Island BioAlliance awarded the Gold Label of Cluster Management Excellence from the European Secretariat for Cluster Analysis (ESCA). This achievement highlights the strength and competitiveness of the bioscience sector in Prince Edward Island, having advanced and grown the sector to 60 companies providing jobs for 2,200 people and attracting $100M in investment in 2021. Learn more. 

Kudos to VoxCell BioInnovation, winner of the 2023 Innovate BC Ignite Award in the Life Sciences and Advanced Health category and awarded $300K for their development of vascularized cancer tissue models. Learn more about these awards and see the complete list of winners here.

The Gairdner Foundation has announced the five winners of its 2023 Gairdner Early Career Investigators (ECI) competition. The winners will present their research alongside the 2023 Canada Gairdner Award laureates during Gairdner Science Week 2023 events in Toronto in Oct. Learn more. 

People on the Move

Earlier this year Genome BC welcomed Candice Loring as Director of Indigenous Relations and Initiatives. Loring is an adjunct professor in the Faculty of Management at the University of British Columbia, Okanagan and is a member of the Gitwangak band from the Gitxsan Nation in Northern BC.

Aspect Biosystems has appointed Lloyd Mackenzie as Chief Technical Operations Officer. Mackenzie brings over 25 years of strategic leadership experience spanning all stages of drug development across therapeutic areas.

Co-founder of SaNOtize, Gilly Regev, is stepping into the Chief Strategy and Innovation Officer role. Steven Basta joins the organization as CEO, with 20+ years of experience leading publicly and privately held companies. Learn more.

The University Health Network (UHN), the largest research hospital in Canada, has announced the appointment of Dr. Bo Wang as the country's first Chief Artificial Intelligence (AI) Scientist. Dr. Wang brings extensive expertise in machine learning, computational biology, and computer vision to drive cutting-edge advancements in healthcare. This significant milestone comes on the heels of UHN's recent launch earlier this year: the UHN AI Hub.

Applications Open

The Ontario Bioscience Innovation Organization (OBIO) will host its 2024 Investment Summit in Toronto from Feb 14–16, 2024. The event highlights Canada's top health science companies in various sectors and includes company pitches and one-on-one meetings. OBIO invites high-potential companies, including those from BC, to apply. The initial application deadline is Oct 8, with rolling reviews and limited presentation spots per financing stage. The final deadline is Oct 22. Learn more and apply here.

UBC’s School of Biomedical Engineering (SBME) is now accepting applications for its 2023 SBME Innovates intake. This is an excellent opportunity for early-stage life sciences ventures to access free wet lab space, mentorship, and more. Applications are due Nov 2. Learn more here. 

Applications are now open for the I.D.E.A.L. Bioscience Employer™ Recognition Program by BioTalent Canada. This program recognizes Canadian bio-economy organizations that embrace principles of inclusion, diversity, equity, and accessibility essential for fostering growth and achievement. Applications are due Nov. 3. Learn more and apply here.

The CIHR is seeking applicants for its new CIHR Pan-Canadian Network for HIV/AIDS and STBBI Clinical Trial Research program. This nationally coordinated network will provide expertise, mentorship, training, and strategic support to researchers in Canada for conducting clinical trials in Canada and abroad. Applications are due Feb. 24. Learn more.

adMare BioInnovations has extended the deadline for its BioInnovation Scientist (BIS) Program: Foundations Cohort II to Oct. 3. This 8-week online program equips participants with essential knowledge in therapeutics development and professional skills for success in the Canadian life sciences sector, featuring expert-led courses, practical activities, and networking opportunities. Learn more and apply here.

In collaboration with SSHRC-CRSH, Canadian Heritage, and UK Research and Innovation, Genome Canada has introduced a funding opportunity to synthesize humanities research. Four specialized Knowledge Synthesis Grants will support genomic research with the potential to inform Canadian policy and practice in protecting cultures and histories. Applications are due Dec. 14. Learn more.

We invite you to explore our expanded list of current life sciences application opportunities by clicking on the following link: Applications Open.

The Last Word

If you're in the Prince George area on Oct. 18, you won’t want to miss our annual Showcase: Prince George event highlighting the latest life sciences developments and featuring sector leaders that include Dr. Hossein Kazemian from UNBC, Dr. Marcelo Bravo from Northern Health, and Dr. David Llewellyn from STEMCELL Technologies. Roger Francis from Michael Smith Health Research BC will also provide remarks. Learn more.

We look forward to meeting some of you at the upcoming MedTech Conference in Anaheim, California, taking place from Oct 9 to 11. Several prominent BC MedTech companies will be in attendance, including ARC Medical Devices, QARALOGIC, Response Biomedical, and Total Flow Medical. Discover more about these and other BC MedTech companies with a sneak peek at our conference booklet here.

Until next week,

Wendy and the LSBC team

Evonik Strengthens Its Portfolio of Nanoparticle Technologies and Services for Parenteral Drug Delivery

Evonik is strengthening its platform of parenteral drug delivery solutions with three new standard PLA-PEG di-block copolymers and a new nanoparticle formulation service using sonication technology. The copolymers (RESOMER® RP d) are especially suited to nanoparticle formation and can be used in a wide range of parenteral drug delivery applications including controlled and sustained release drug products... READ MORE

Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine

The updated vaccine is administered as a single dose for individuals 5 years of age and older, regardless of COVID-19 vaccination history. In children 6 months through 4 years of age the vaccine is administered as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course, or as a single dose in those with a history of completion of a COVID-19 primary vaccination course... READ MORE

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to chemotherapy. An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis... READ MORE

Aspect Biosystems to Present at 2023 Cell & Gene Meeting on the Mesa

Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, announced today that CEO Tamer Mohamed will present at the annual Cell & Gene Meeting on the Mesa to be held October 10-12, 2023 in Carlsbad, California and livestreamed globally... READ MORE

SaNOtize’s Board Appoints Steven Basta as New Chief Executive Officer

 SaNOtize Research and Development Corp., a Canadian anti-infective-focused therapeutics company, today announced that the company has appointed Steven Basta, an experienced biopharma and medical device commercial leader, as its new Chief Executive Officer (CEO). Co-Founder Gilly Regev, PhD, will transition from her role as CEO to Chief Strategy and Innovation Officer at SaNOtize and will remain a member of its Board of Directors... READ MORE

Avantor® Announces Ger Brophy to Retire in 2024; Benoit Gourdier Appointed EVP, Biopharma Production

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and technology industries, announced that Benoit Gourdier will join the company as EVP, Biopharma Production on October 2, 2023. Mr. Gourdier will succeed Dr. Ger Brophy, who will retire from the company on February 29, 2024. Following his retirement, Dr. Brophy will continue to serve as an advisor to the company as well as Chair of the Avantor Scientific Advisory Board... READ MORE

DIGITAL Celebrates 5-Year Impact of $190 Million Applied AI Investments & $30 Million Horizon AI Program Launch

Since 2018, DIGITAL has co-invested in over 40 initiatives totaling $190 million in applied artificial intelligence (AI) solutions. These investments are building on Canada’s reputation as a global center for AI R&D with a focus towards advancing global commercial pathways for Canadian companies. Across the over 300+ organizations DIGITAL has worked with on these initiatives... READ MORE

GSK Announces Largest Private Financial Contribution to CIHR’s Team Grants Initiative Addressing Threats to Canadian Lung Health

GSK is investing $2 million in research to address ongoing, new, and emerging threats to lung health in Canada. The funds will be managed and administered by the Canadian Institutes of Health Research (CIHR) through the Team Grants in Lung Health initiative. GSK’s contribution is the largest private financial contribution to this research initiative to date... READ MORE

Mesentech Doses First Patients with Investigational Drug MES1022 to Accelerate Healing of Bone Fractures

Mesentech, a biotech company developing novel tissue-selective therapies to treat bone diseases, announced that it has dosed the first patients in its Phase 1 study for MES1022, a bone regeneration drug which enhances efficacy and avoids systemic exposure and side-effects by selectively distributing to bony tissues... READ MORE

STEMCELL Technologies Partners with Science World to Empower Girls Pursuing Science-related Careers

STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce it will be the presenting partner of the Girls and STEAM Summit at Science World in Vancouver. The Summit, which takes place on November 4, 2023, is a full-day event with workshops, hands-on activities, a keynote presentation, and sessions with experienced mentors who work in STEAM (science, technology, engineering, art and design, and math)... READ MORE

Empowering Change: Biotalent Canada Opens Second Annual I.D.E.A.L.Bioscience Employer™ Recognition Program

BioTalent Canada is now accepting new applications for its I.D.E.A.L. (Inclusion, Diversity, Equity and Accessibility Leadership) Bioscience EmployerTM Recognition Program, building on the success of last year’s inaugural initiative... READ MORE

NervGen Pharma Announces First Subject Dosed In Landmark Phase 1b/2a Clinical Trial For NVG-291 In Spinal Cord Injury

NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the first subject has been dosed in the Company’s landmark Phase 1b/2a proof-of-concept placebo-controlled clinical trial for its proprietary lead compound, NVG-291, in individuals with spinal cord injury (SCI)... READ MORE

PharmAla Receives First Office Action for PharmAla-1 PCT Filing

PharmAla Biotech Holdings Inc., a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is proud to announce that it has received the first office action from the Patent Cooperation Treaty (PCT) filing for the company’s novel PharmAla-1 (P-1) molecule. The filing for P-1 showed the molecule to be novel, with no previous Prior Art shown; It was also found to be inventive, due to the beneficial toxicology of P-1 compared to similar molecules, as shown by preclinical rodent model data generated by the laboratory of Prof. William Fantegrossi at the University of Arkansas for Medical Sciences... READ MORE

Genome BC Welcomes Candice Loring as Director, Indigenous Relations and Initiatives

Candice will be a strategic advisor for how Genome BC engages with Indigenous communities, working across the organization to ensure Indigenous communities are involved in the process of research and innovation under Genome BC programs, building relationships and partnerships, and ensuring that Indigenous peoples are being seen, heard and treated as rightsholders... READ MORE

Zucara Therapeutics Doses First Patient in Phase 2a ‘ZONE’ Trial

Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, announced that it has dosed the first patient in its Phase 2a trial of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes (“T1D”) mellitus (“ZONE”)... READ MORE

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced the Company received written notice from the listing qualifications department staff of The Nasdaq Capital Market dated September 19, 2023, notifying that the closing bid price of the Company’s common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550(a)(2)... READ MORE

United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the achievement of two milestones for its xenotransplantation programs in September: the second transplant of a UHeart™ xenoheart into a living person, and a 61-day study of the UThymoKidney™ xenokidney and thymus in a human pre-clinical model... READ MORE

Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director and Enters Cooperation Agreement With Shareholder Mkt Capital

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) announced that its Board of Directors (“the Board”) has appointed Dr. Robert T. Foster to the Board. MKT Capital Ltd. (together with its affiliates, “MKT Capital”) submitted Dr. Foster as a candidate and worked collaboratively with Aurinia to name him to the Board... READ MORE

League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease

In honor of Hispanic Heritage Month, Bausch Health Companies Inc. (NYSE/TSX: BHC) and its oral health care business, OraPharma, announced its collaboration with the League of United Latin American Citizens (LULAC) – the largest and oldest Hispanic organization in the United States – to foster a greater understanding of gum disease detection, and treatment within the Hispanic community... READ MORE

Microbiome Insights, Inc. is a global leader providing end-to-end microbiome sequencing and comprehensive bioinformatics analysis. The company is headquartered in Vancouver, Canada, where samples from around the world are processed in its College of American Pathologists (CAP) accredited laboratory.

Working with clients from pharma, biotech, nutrition, cosmetic and agriculture companies, and world-leading academic and government research institutions, Microbiome Insights has supported over nine hundred microbiome studies, from basic research to commercial R&D and clinical trials. The company's expert bioinformaticians and data scientists deliver industry-leading insights, including biomarker discovery, machine-learning-based modelling, and customized bioinformatics analysis. LEARN MORE

Minister Champagne Launches Voluntary Code of Conduct Relating to Advanced Generative AI Systems

The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, announced Canada’s Voluntary Code of Conduct on the Responsible Development and Management of Advanced Generative AI Systems, which is effective immediately. The code identifies measures that organizations are encouraged to apply to their operations when they are developing and managing general-purpose generative artificial intelligence (AI) systems... READ MORE

Prince Edward Island Bioalliance Receives Gold Label of Excellence From International Cluster Audit Organization

As Canada celebrates Global Biotech Week, the Prince Edward Island bioscience cluster continues to establish its reputation nationally and internationally. The Prince Edward Island BioAlliance has been awarded the Gold Label of Cluster Management Excellence by the European Secretariat for Cluster Analysis (ESCA). The ESCA provides benchmarking and quality labelling of cluster management organizations worldwide... READ MORE

Capital Compass BC Offers Expansive View Into Province’s Capital and Business Landscape

Innovate BC, InBC Investment Corp. (InBC), PacifiCan and New Ventures BC have partnered to launch a new online platform that provides a comprehensive and dynamic view of British Columbia’s capital and business landscape. Available now, Capital Compass BC offers centralized intelligence on startups, scaleups, investors, entrepreneurial resources, and investment capital flow within the province... READ MORE

Canada Welcomes Japan’s Minister of Economy, Trade and Industry

The Honourable Mary Ng, Minister of Export Promotion, International Trade and Economic Development, along with the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jonathan Wilkinson, Minister of Energy and Natural Resources, welcomed Yasutoshi Nishimura, Japan’s Minister of Economy, Trade and Industry, to Ottawa... READ MORE

Research Associate-Protein Biochemistry

Abdera Therapeutics is seeking a highly motivated and skilled Research Associate in antibody discovery programs. This position will provide an exciting and dynamic opportunity to positively contribute to research programs developing next-generation targeted radiopharmaceutical therapies...LEARN MORE

Senior Scientist Biologics

Abdera Therapeutics is seeking a highly motivated and skilled Senior Scientist in antibody discovery programs with a proven track record of research accomplishments. This position will provide an exciting and dynamic opportunity to positively contribute to research programs developing next-generation targeted radiopharmaceutical therapies...LEARN MORE

Research Associate II, Analytics

The candidate should have expertise in high-performance liquid chromatography (HPLC), mass spectrometry, and protein biochemistry for protein characterization. Experience with various extraction techniques, Agilent™ or Waters™ HPLC and mass spectrometry equipment, AKTA™ purification systems, biological matrices like plasma and serum, and Orbitrap™ mass spectrometry instrumentation would be advantageous. General knowledge of antibody and antibody drug conjugate structure/function is also considered a valuable asset...LEARN MORE

Animal Research Associate II

This role involves applying preclinical mouse pharmacology models for cancer therapy research. Responsibilities include handling mice for various procedures, preparing drugs using sterile techniques, managing human immune cell injections, coordinating sample handling, maintaining records, and ensuring adherence to scientific standards and regulations. Effective organization, teamwork, and adherence to established protocols are essential, while fostering collaborative relationships with colleagues and management is encouraged...LEARN MORE

Senior Research Associate I, In Vitro Pharmacology

This position involves planning and executing advanced experiments, troubleshooting methods, and independently analyzing and interpreting data. The role includes designing animal studies, contributing to project planning and coordination, staying updated on relevant scientific literature, maintaining inventory databases, and potentially training junior staff. The candidate is expected to adhere to scientific standards, safety regulations, and lab protocols while actively contributing to collaborative work environments and potentially co-authoring scientific papers...LEARN MORE

Scientist, DMPK/ADME

If you are selected for this position, you will be lead oversight of contract research partners and in-house development of in vitro DMPK assays, contributing to their optimization and methodology enhancement. Independently design experiments for assessing pharmacokinetics and pharmacodynamics of small molecules and ADCs, establishing in vitro to in vivo correlations, and collaborating across disciplines to advance drug development programs. Maintain up-to-date knowledge in drug metabolism and pharmacokinetics, adhere to data generation protocols, and foster collaborative relationships with colleagues and management...LEARN MORE

Associate Scientist, In Vivo Pharmacology

The ideal candidate should have expertise in xenograft, syngeneic, or humanized mouse tumor models (PBMC/CD34) and a strong grasp of immune cell function. Proficiency in animal handling, dosing, and sample collection, especially tail vein injections, is essential. They should also demonstrate knowledge of in vivo cancer models, antibody-based therapeutics, immune cell isolation, strong organizational skills, experience with contract research organizations, and effective teamwork within scientific project teams...LEARN MORE

Controller

The Employee will carry out standard job responsibilities and any additional tasks assigned by the Company, including financial management, policy enforcement, budgeting, tax coordination, audit oversight, control maintenance, reporting enhancement, compliance support, variance analysis, insurance management, stock options, governance assistance, benefits administration, and other duties as directed by the CFO and Executives...LEARN MORE

Quality Assurance Specialist

Filament Health is looking for an enthusiastic individual with a keen eye for detail to fill the role of Quality Assurance Specialist with experience in the pharmaceutical industry. Reporting to the Quality Director, the ideal candidate will be a self-starter who needs minimal oversight and thrives in a dynamic work environment. They will provide quality support to ensure adherence to Good Documentation and Production Practices, Health Canada regulations as well as international jurisdictions such as the US, EU, UK and Australia...LEARN MORE

Project Coordinator, Research and Innovation (R&I)

As the Project Manager for Research and Innovation (R&I) Agrifood and Natural Resources (ANR), you will primarily provide project management and administrative support to the R&I Senior Manager, ANR. Additionally, you will informally report to the Director of Operations to ensure alignment with processes and effective reporting of any issues that may arise during project management...LEARN MORE

Events Specialist (Co-op Student)

Life Sciences BC is looking for an enthusiastic new co-op student to assist with

preparations and execution of both in-person and virtual events. With several scheduled events happening between January and April, this role will offer a varied mix of tasks and projects and will provide fantastic experience for the chosen candidate to see how a professional industry association operates. This position will report to the Manager, Events...LEARN MORE

Partnerships & Memberships Specialist (Co-op Student)

Life Sciences BC is looking for an enthusiastic new co-op student to help maximize potential revenue opportunities and lead generation throughout the term. This role will offer a varied mix of tasks and projects and will provide fantastic experience for the chosen candidate to see how a professional industry association operates. This position will report to the Manager, Partnerships and Memberships...LEARN MORE

Marketing & Communications Specialist (Co-op Student)

In this limited-term role, you'll work alongside our Marketing and Communications Manager, contributing your skills to the planning and execution of diverse marketing and communications initiatives. This is an exceptional chance to acquire practical expertise while leaving your mark on both the life sciences field and the world of marketing and communications...LEARN MORE

Vice President, Corporate Development

The VP, Corporate Development supports the delivery of the corporate mandate in close cooperation with other members of the management team by: building relationships with key stakeholders, including government; delivering cross-functional programs and initiatives; and, taking the lead on emerging opportunities...LEARN MORE

Canada’s Immuno-Engineering and Biomanufacturing Hub - Industry Partnership Manager

Working under broad directions of the Executive Director of CIEBH, the Industry Partnership Manager will develop and mobilize academic and hospital discoveries originating from the University and its Affiliated Hospitals, through fostering sponsored research, supporting entrepreneurship, developing and implementing knowledge mobilization plans, engaging with researchers and industry, and conducting evaluations...LEARN MORE

Scientist, Preclinical Research

Bold Therapeutics is seeking to hire a Scientist to join and expand their preclinical research team. A successful candidate will support Bold Therapeutics’ preclinical oncology research efforts, with a focus on cellular biology and understanding the mechanism of action of BOLD-100 and our other metallotherapeutics. The role involves collaborating with Bold Therapeutics’ research team, as well as our network of academic and industry partners, to advance the understanding of our key assets...LEARN MORE

Postdoctoral Position at Eyam Vaccines and Immunotherapeutics - Bioinformatician

This is a unique opportunity to experience collaborative research with leading industry and academic experts. The successful candidate will work both in-person, on site at our Vancouver/Greater Vancouver Area offices, and remotely on a project to create and use novel algorithms for the development of self-amplifying nucleic acid vaccines...LEARN MORE

Administrative Assistant, Research and Innovation

The position is responsible for providing administrative support to the two Research and Innovation Directors (Director, Research and Innovation Operations and Director, Data Science) and three Senior Managers (Senior R&I Manager, Health; Senior R&I Manager, ANR; Senior Programs Manager). As well as supporting the R&I Senior Management Team by coordinating, organizing, and executing general administrative duties, coordinating meeting logistics, providing general meeting support, executing travel and event management, and performing expense/invoice processing...LEARN MORE

Animal Technician

Alpha-9 is seeking a team-oriented Animal Research Technician to join the Translational Biology group within the organization. The ideal candidate will have experience in providing technical in vivo support for research programs, preferably with radioactive substances. This person will be responsible for laboratory animal care and well-being, in addition to conducting in vivo research experiments with experimental radiopharmaceuticals...LEARN MORE

Tenure-Track Assistant Professor Positions (2) Nanomedicine or Chemical Biology

UBC is seeking two full-time tenure-track Assistant Professor positions in their Nanomedicine and Chemical Biology Research Theme, where the research programs focus on many aspects of drug discovery, development and delivery. The major focus of this position will be the development of a cutting-edge, externally-funded, world-class research program. Other responsibilities will include teaching nanomedicine/drug delivery or chemical biology and other related topics to students in the BPSc, PharmD, and MSc/PhD programs, as well as new programs under development...LEARN MORE

Destination Vancouver is the non-profit, member-led destination management organization for the spectacular city of Vancouver, BC.

One of the organization's many purposes is to transform the community via connecting local industry experts/academics/thought leaders in Vancouver with national and international sized business events that showcase their work, their industry, organizations and institutions.

LEARN MORE

The Terry Fox Research Institute has invested in groundbreaking scientific projects that accelerate discoveries for the benefit of cancer patients.

Today, this investment expands beyond our flagship basic science and translational research programs. With support from partners across the country, including the Government of Canada, we now lead two innovative projects that embody Terry Fox's spirit and unite our country to improve the lives of cancer patients through precision medicine: the Marathon of Hope Cancer Centres Network and the Digital Health and Discovery Platform.LEARN MORE

Stay current by subscribing to this and our events newsletter!

Follow LSBC on Social Media!